Profitability • Coherus BioSciences
CHRS
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
44,7%
Gross Margin
Gross margin measures the amount of revenue that remains after subtracting costs directly associated with production.
12,3%
EBITDA Margin
The EBITDA margin is a measure of a company's operating profit desconsidering D&A costs as a percentage of its revenue.
—
Normalized EBITDA Margin
The Normalized EBITDA margin is a measure of a company's operating profit without unusual items desconsidering D&A costs as a percentage of its revenue.
10,5%
EBIT Margin
The EBIT margin is a measure of a company's operating profit considering D&A costs as a percentage of its revenue.
—
Net Margin
The net profit margin, or simply net margin, measures how much net income or profit is generated as a percentage of revenue. It is the ratio of net profits to revenues for a company or business segment.
14,2%
D&A/EBITDA
Many companies have a high D&A in relation to the company's operating profit (EBITDA) and although this indicator does not have an effective cash effect, it ends up influencing the accounting net income, so analyzing this relationship can help to understand when D&A has a relevant impact to the company's results.
0%
D&A/Normalized EBITDA
Many companies have a high D&A in relation to the company's normalized operating profit (Normalized EBITDA) without unusual items and although this indicator does not have an effective cash effect, it ends up influencing the accounting net income, so analyzing this relationship can help to understand when D&A has a relevant impact to the company's results.
33,9%
R&D/Revenue
Shows the amount spent on investments in research and development in relation to the Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
0%
Capex/Revenue
Shows the amount spent on investments in Capex in relation to Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
0%
Capex/D&A
Indicates a comparison between investments in fixed/intangible assets and the depreciation and amortization of some company assets. It serves to let managers know that the company's assets are devaluing periodically, and whether CAPEX has followed the same pace or not.
0%
Capex/OCF
It shows the percentage of operating cash flow that the company uses in Capex (investments in fixed and intangible assets). When your result is greater than 100%, it demonstrates that there are expenses greater than what the company produces in its operations.
—
SBC/OCF
It demonstrates the percentage cost of Stock-Based Compensation compared to the company's operating cash flow. In some companies, the OCF is positive because of the SBC, which can lead to an incorrect cash flow analysis.
—
SBC/FFO
It demonstrates the percentage cost of Stock-Based Compensation compared to the REIT's FFO. In some companies, the FFO is positive because of the SBC, which can lead to an incorrect cash flow analysis.
11,7%
SBC/EV
Compares Stock-Based Compensation spend with Enterprise Value, which adjusts the company's market value to a multiple closer to its true value, also considering debt and cash on hand. your calculation.
0,6%
% PPE
If the company has a lot of D&A, it helps to see if most of it tends to come from fixed assets. The account can include machinery, equipment, vehicles, buildings, land, office equipment, and furnishings, among other things.
10,8%
% Intangible
If the company has a lot of D&A, it helps to see if most of it tends to come from intangible assets. The account can include rights or economic benefits, such as patents and goodwill, that is not physical in nature.
0%
% Goodwill
If the company has a lot of D&A, it helps to see if most of it tends to come from Goodwill, that is an intangible asset that accounts for the excess purchase price of another company.
—
ROE
Return on equity (ROE) is the measure of a company's net income divided by its shareholders' equity and is a gauge of a corporation's profitability and how efficiently it generates those profits.
—
ROA
Return on assets is a metric that indicates a company's profitability in relation to its total assets and can be used by management, analysts, and investors to determine whether a company uses its assets efficiently to generate a profit.
—
ROIC
Return on invested capital (ROIC) is a calculation used to assess a company's efficiency in allocating capital to profitable investments. The formula for calculating ROIC in Morningstar involves dividing Net Income by the average of invested capital.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!